Texas Biomedical Research Institute

Donate by phone 210-210-9755

CORONAVIRUS (COVID-19)

Call To Action

Texas Biomed scientists are working to develop diagnostics, therapeutics and prevention methods of COVID-19. Critical research is needed to study this novel and highly transmissible virus spreading around the world. Donations allow Texas Biomed to further its research to combat COVID-19, keeping our communities safe. Texas Biomed is a 501(c)(3) and will provide a tax receipt to all donors.

Coronavirus (COVID-19)

The spread of coronavirus (SARS-COV-2) over the last five months has become a major global pandemic. The virus is impressively infectious, causing acute respiratory distress syndrome (ARDS) in the elderly and others with compromised immune systems. It is the most vulnerable among us who are at highest risk.

To date, no known cures or vaccines exist. It is critical to develop appropriate animal models for the development of potential vaccines and treatments to move through clinical and human trials to ensure these drugs are safe and effective. Texas Biomed’s mission is to eradicate infectious diseases around the world. As a private non-profit institution, we are providing a nimble and accelerated method for moving a drug from discovery to the market.

Our successful track record includes creating animal models for vaccines and therapies, which are now being used to treat Ebola, AIDS, ZIKA and Hep-C. Texas Biomed is in a unique position to be among the first in the world to provide an animal model required to test Cornonavirus vaccines and treatments. Texas Biomed has begun the groundbreaking research necessary to deliver this critical model. This emergency effort requires financial support along with scientific expertise to fast track the research. Once delivered, this model will enable  researchers worldwide to begin pre-clinical testing of diagnostics, treatments and vaccines that will save lives.

Investment in Texas Biomed directly supports the country’s efforts to expedite development, stockpiling and ultimate use of new diagnostics, therapies and vaccines at the preclinical level. The fully integrated R&D plan for infectious disease research at Texas Biomed enables preclinical science to move from REACTING to outbreaks to PROACTIVELY planning ahead for the next one, a sustained leadership force in the industry.